CURRICULUM VITAE

Date Prepared: March 6th 2009

NAME Christiane Ferran, M.D., Ph.D.

OFFICE ADDRESS Center for Vascular Biology Research
Divisions of Vascular Surgery and Nephrology
Departments of Medicine and Surgery
Beth Israel Deaconess Medical Center,
99 Brookline Avenue, Boston MA 02215
Tel: 1-617- 6670440

E-MAIL: cferran@caregroup.harvard.edu **Fax:** 1- 617-6670445

CITIZENSHIP US Citizen

PLACE OF BIRTH Beirut, Lebanon

EDUCATION

1977	B. S.	Jamhour College, Beirut Lebanon
1983	M. D.	Saint Joseph University, French Doctorate
1987	Nephrology Board	University Paris V, Paris France
1988	M.S.	Institute Pasteur, Paris France
1992	Ph.D. Immunology	University Paris VII, Paris, France

POSTDOCTORAL TRAINING

Internships and Residencies

1981-1983 Rotating internship in medicine, surgery, pediatrics, emergency medicine and intensive care medicine, Saint George's Hospital, Beirut, Lebanon

1984-1986 Residency in Nephrology, Clinique Néphrologique de L'Hôpital Necker, Paris, France

1986-1987 Chief Resident (Resident of the College de France) in Nephrology, Clinique Néphrologique de L'Hôpital Necker, Paris, France

Clinical and Research Fellowships

1988-1991 Fondation pour la Recherche Médicale (FRM) research fellowship, INSERM U25, Hospital Necker, Paris France

1990 Research Fellowship, Department of Pathology and Molecular Biology, Washington, School of Medicine, Saint Louis, Missouri, USA

1991-1992	Fondation pour la Myasthénie Research fellowship, INSERM U25, Hospital Necker, Paris, France
1993-1995	Sr. Research Associate/Research Fellow, Deaconess Hospital/Harvard Medical School, Department of Surgery, Boston, MA
1997-1998	Nephrology Fellowship, Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Internal Medicine , Boston, MA

LICENSURE AND CERTIFICATION

1983	License in Medicine, Lebanese State Registration in Medicine
1987	License in Medicine and Nephrology, French National Order of Medical Doctors
1995	ECFMG (Educational Commission for Foreign Medical Graduate) certified. USMLE (United States Medical License Examination), step I and step II Boston USA (September 1994, August 1995)
1998	USMLE step III (May 1998)
1999	License in Medicine, Commonwealth of Massachusetts Board of Registration in Medicine

ACADEMIC APPOINTMENTS

1991-1993	Instructor of Transplantation Immunology and Nephrology, Paris University, France
1995- 1997	Instructor in Surgery, Harvard Medical School, Boston MA
1997- 1999	Assistant Professor of Surgery, Harvard Medical School, Boston MA
2000-present	Associate Professor of Surgery, Harvard Medical School, Boston, MA
2001-present	Associate Professor of Medicine, Harvard medical School, Boston, MA

HOSPITAL APPOINTMENTS

1988-1991	Covering Attending Physician, Division of Kidney Diseases and Transplantation, Necker Hospital, Paris, France.
1988-1991	Part-time Attending Physician in Nephrology and dialysis, Compiègne clinic, France.
1990-1993	Attending Physician in Nephrology, ANDRA Nephrology Clinic, Paris, France.
1995-1996	Assistant Scientist, Department of Surgery, Deaconess Hospital, Boston, MA.
1996-1997	Assistant Scientist, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA.
1997- 1998	Nephrology Fellow, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA
1999-present	Staff MD, Division of Vascular Surgery, Department of Surgery and the Renal Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA

OTHER PROFESSIONAL POSITIONS AND MAJOR VISITING APPOINTMENTS

1990	Visiting Research Fellow, Department of Pathology, Washington University, Saint Louis, MO.
2004-present	Member of the Transplant Research Center, Beth Israel Deaconess Medical Center, Boston, MA. Director: Terry Strom ,MD.
2006-present	Member of the Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston, MA. Director: William Aird,MD.

MAJOR ADMINISTRATIVE RESPONSIBILITIES

2008-present	Head of the Subcommittee for Junior Investigators at the Center for Vascular Biology Research, Beth Israel Deaconess Medical Center. This Subcommittee is aimed at mentoring the Junior Faculty of the Center in their career development with particular emphasis on their pursuit of independent funding.

MEMBERSHIPS AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES

1988	Member of the French Society of Nephrology
1989	Member of the French Society of Transplantation
1994	Member of the International Society of Organ Transplantation
1995	Honorary Member of the Lebanese Society of Nephrology and Hypertension
1998	Member of the American Society of Nephrology
1999	Member of the American Society of Transplant Physician
2000	Scientific reviewer for the Juvenile Diabetes research Foundation International (JDRFI)
2005	Reviewer for the NIH-NIDDK SRG: Pilot and Feasibility Program in Islet cell Biology (December 1st –December 2nd 2004, Bethesda, MD)
2005-	Member of the Scientific Advisory Committee (SAC) of the Roche Organ Transplantation Research Foundation (ROTRF)
2005	Reviewer for the NIH-NIDDK SRG: Special emphasis panel, Ancillary Studies to Major Ongoing NIDDK Clinical Research Studies PAR-04-078 (July 22nd 2005).
2005	Reviewer for the American College of Cardiology 2006
2005-2006	Reviewer For the Wiener Wissenschafts Forshtungs und Technologiefonds, Vienna Austria.
2006	Reviewer for the NIH-NIDDK SRG, ZDK1 GRB-G M41, Special emphasis panel, Ancillary Studies to Major Ongoing NIDDK Clinical research Studies PAR-04-078 (March 23rd 2006)
2006	Reviewer for the World Transplant Congress (July 2006, Boston, MA, USA)
2006	Reviewer for the Boston Association in Diabetes and Endocrinology Research (BADERC).
2006	Reviewer for the NIH Study Section Tolerance, Transplantation and Tumor Immunology (TTT) (October 9-10, 2006)
2007	Reviewer for the NIH Study Section Tolerance, Transplantation and Tumor Immunology (TTT) (May 31-June 1, 2007)
2008	Reviewer for the American Transplant Congress 2008.

2008	Reviewer for the XXII International Congress of the Transplantation Society.
2009	Reviewer for the NIH-NHLBI/NIAID Scientific Review Group ZRG1 2009/05 Immunology IMM-G(02) Special Emphasis Panel. Immunology: Member Conflicts and Special Grant Applications (February 17th-18th, 2009).

AWARDS AND HONORS

1987	College de France fellowship
1988	Fondation pour la Recherche Médicale (FRM) Research Award Fellowship
1991	Fondation pour la Myasthénie Fellowship
1991	Institute Electricité-Santé of France Annual Research Award
1992	Paul Neumann Prize, Prize of the French Society of Nephrology
1993	Post-doctoral Research grant of the Fondation Pour La Recherche Médicale (FRM)
1998	Nominated by Harvard Medical School for the Burroughs Wellcome Award in translational Research
1996-present	Reviewer for Several peer review highly ranked journals including: Journal of Clinical Investigation, Blood, Circulation, Arteriosclerosis Thrombosis and Vascular Biology, Diabetes, Genes and Development, Transplantation, Journal of Immunology, American Journal of Rheumatology, American Journal of Transplantation, American Journal of Kidney Diseases, Nephrology Dialysis and Transplantation, Oncogene, Cancer Research, Cell And Experimental Research and Kidney International
2002	Mary Jane Kugel Award. Juvenile Diabetes Foundation International
2004	Reviewer for the NIH/NIDDK. SRG: Pilot and feasibility program in islet cell biology (December 1st –December 2nd 2004, Bethesda, MD)
2005	Reviewer for the NIH/NIDDK Special emphasis panel: ZDK1 GRB-G. Ancillary Studies to Adult Liver Transplantation Clinical Research (July 22nd 2005)
2005-present	Member of the Scientific Advisory Committee for the Roche Organ Transplant Research Foundation (ROTRF)
2005	Reviewer for the American College of Cardiology 2006
2006	Reviewer for the NIH/NIDDK Special emphasis panel: ZDK1 GRB-G. Ancillary Studies to Adult Liver Transplantation Clinical Research (March, 2006)
2006	Reviewer for the World Transplant Congress (July 2006, Boston, MA)
2006-2007	Reviewer for the NIH Study Section Tolerance Transplantation and Tumor Immunology (TTT) (October 9-10, 2006; May 31-June 1, 2007)
2008	Reviewer for the American Transplant Congress 2008 (May 31st -June 4th 2008, Toronto, Canada)
2008	Reviewer for the XXII International Congress of the Transplantation Society (10-14 August 2008, Sydney, Australia)
2009	Reviewer for the NIH-NHLBI/NIAID Scientific Review Group ZRG1 2009/05 Immunology IMM-G(02) Special Emphasis Panel. Member Conflicts and Special Grant Applications (February 17th-18th, 2009)

MAJOR RESEARCH INTERESTS

1. Vascular biology: Functions of "protective", homeostatic genes expressed in both endothelial cells and smooth muscle cells in protecting from atherosclerosis and transplant-associated vasculopathy with a particular emphasis on their use as gene therapy tools for the prevention and cure of atherosclerosis, transplant associated vasculopathy and diabetic vasculopathy. Molecular basis for abnormal angiogenesis in the context of diabetic retinopathy
2. Islet cell transplantation in type I auto-immune diabetes mellitus including genetic engineering of the β-cell
3. Role of cytoprotective and anti-inflammatory proteins in the prevention of experimental acute toxic or viral hepatitis and ischemia reperfusion injury and in promoting liver regeneration
4. Immunosuppressive therapies in organ transplantation

NARRATIVE REPORT OF RESEARCH, TEACHING AND CLINICAL CONTRIBUTIONS

Eighty per cent of my time effort is devoted to Research and the other twenty per cent for teaching and administrative tasks. My major research interests are in the field of vascular biology, micro and macrovascular complications of diabetes, liver and β-cell regeneration, transplantation including xenotransplantation and islet transplantation and autoimmune diabetes. More specifically, the work in my laboratory is focused on the understanding of the function (s) of the cytoprotective genes A20, Bcl-2, Bcl-x_L and A1 in different cell types, their relationship to the pathophysiology of diseases and their potential therapeutic use in atherosclerosis, organ transplantation, diabetes and hepatitis. This interest is based on our original finding that these genes serve a broad cytoprotective function in endothelial cells. Expression of A20, A1, Bcl-2 and Bcl-x_L in endothelial cells not only protects the cells from apoptosis but also serve a broad anti-inflammatory purpose.

We now have expanded the work to other cell types and made five additional critical observations. First that A20 retains in β-cells its anti-apoptotic an anti-inflammatory potential and thus is an ideal candidate to genetically engineer islet grafts for the treatment of diabetes. Second that A20 serves an anti-atherogenic function in smooth muscle cells via inhibition of cell proliferation and induction of apoptosis in neointimal smooth muscle cells. Third, that A20 levels are decreased in diabetic patients and diabetic animals. A20's decrease is due to unique glucose-dependent post-translational O-glycosylation that acts as a flag for subsequent ubiquitination and degradation in the proteasome. Loss of this important atheroprotective mechanism is part of the molecular basis for the increased risk of atherosclerosis in diabetes. This work was recently submitted for publication in the FASEB Journal. Fourth, that A20 also demonstrate a potent anti-angiogenic function in retinal endothelial cells. Here again, diabetes-related degradation of A20 would significantly contribute and aggravate heightened angiogenesis in diabetic retinopathy. We are mapping and mutating the glycosylation sites within A20. Glycoslation resistant A20 should be able to sustain the insults of high glucose as to provide adequate atheroprotective and anti-angiogenic effects to protect from macro and microvascular complications of diabetes. Fifth, that A20 protects mice from lethality in a model of acute toxic hepatitis and lethal radical hepatectomy by promoting hepatocyte survival, containing inflammation and unexpectedly promoting their proliferation by shutting down the cell cycle inhibitor: $p21^{waf1}$ and also promoting IL-6 proliferative signals by shutting down SOCS-3. This latter work is being finalized for publication. Sixth, that Hepatocyte Growth Factor is upregulating A20 in renal proximal tubular epithelial cells and endothelial cells by

engaging the non-canonical form of NF-κB without promoting any inflammation. These results could be particularly important for the design of preventive or pre-conditioning regimen that would limit inflammation in many disease processes including prior to major vascular interventions and organ transplantation. This work is being finalized for publication and has been already presented at National and International Meetings. We hope that data obtained in experimental models will set the basis for the therapeutic use of these proteins in clinical settings. We are also working on defining at the molecular level the intracellular targets that account for the function(s) of these proteins, and on establishing a structure/function analysis to map the domains associated with their different functions. As part of this work we discovered, in collaboration with Dr. Pope from Northwestern University in Chicago, that A20 interrupts caspase-independent cell death in macrophages and in collaboration with Dr. Roya Khosravi-Far from the BIDMC, that A20 was involved in the resistance of cancers to TRAIL. These findings were respectively accepted for publication in the Apoptosis Journal and submitted for publication. It is our hope that defining specific domains and targets responsible for the function(s) of these genes may allow the development of peptide-based therapies and drug-design strategies.

The personnel effort is equally divided between the clinically oriented projects and the basic science projects. Two post-doctoral research fellows, one graduate student , one research associate, two T32 residents in Surgery, an Instructor, an Assistant Professor and a visiting Surgery fellow from Switzerland are currently working in the laboratory. I provide a direct supervision of all the projects in my laboratory as well as for the T32 trainees in Vascular Surgery who are in Dr. Logerfo's laboratory, given my role as a co-director of this training grant. This includes informal teaching sessions, technical help if required, experimental design, literature search and manuscript writing. All of which is part of my teaching responsibilities.

In addition, I have recently agreed to head the Subcommittee for Junior Investigators at the Center for Vascular Biology Research, Beth Israel Deaconess Medical Center. This Subcommittee includes as members Drs. William Aird (Director of the CVBR) and Dr. Laura Benjamin (co-director of the CVBR). This major endeavor involves meeting with the Junior Faculty members on a regular basis to help them prioritize their work and focus their Science, guide them in approaching different funding agencies, provide help in terms of grantsmanship and edit their proposals or seek the help of a the most appropriate senior colleague from the Center to do so. Approximately 10% of my time has been devoted to this work that I consider to be a critical part of my teaching and mentoring responsibilities.

RESEARCH FUNDING INFORMATION

Jan. 1998-Dec. 2001	NIH/NHLBI RO1 Grant # HL57791 Principal Investigator: C.Ferran Title: "Modulation of Endothelial Cell Response by A20"
Dec. 1997-Nov. 2002	NIH/NIDDK Program Project Grant, PO1# DK53087 Principal Investigator: C. Ferran Program Director: Pr. Gordon Weir, Joslin Clinic Title: "Genetic Engineering of Xenogeneic Islets with Anti-apoptotic Genes and Cytokine Inhibitors"

Sep. 1998-Aug. 2003	Harvard Institute for the Cure of Juvenile Diabetes funded by the Juvenile Diabetes Research Foundation International (JDRFI) Principal Investigator: C. Ferran Program Head: Pr. Hugh Auchincloss Jr. Title: " Role of the anti-apoptotic gene A20 in prevention of auto-immune diabetes in NOD mice"
Sep. 1998- Aug. 2002	NIH/NHLBI RO1 Grant # HL58688 Co-investigator: C.Ferran Principal Investigator: Dr. Fritz H. Bach. BIDMC Title: Xenotransplants: "Genetically engineered endothelial cells"
Oct 2001-Dec 2004	Roche Organ Transplantation Research Foundation Principal Investigator: C. Ferran Title: "Protective effect of A20 against Transplant-Associated Vasculopathy"
Sep. 2002- Aug. 2004	NIH/NIDDK RFA 1 R21 DK062601 Principal Investigator: C. Ferran Title: " Gene transfer with A20 to improve islet transplantation "
Jan. 2003- May 2009	NIH/NIDDK 1RO1 DK63275 Principal Investigator: C. Ferran Title: "Improved liver function and regeneration with A20" The competitive renewal of this grant received a score of 113 and a percentile of 0.9 and **we expect it to be renewed until at least June 2013**
July 2004- May 2009	NIH/NHLBI 1RO1HL021796-23 Co-investigator: C. Ferran Principal Investigator: Dr. Frank W. LoGerfo Title: "Mechanisms of prosthetic arterial graft failure"
Oct 2005-Sept 2006	JDRF grant #5-2005-1276 Principal Investigator: C. Ferran Title: Altered A20 expression in diabetic retinopathy
Feb 2006-Mar 2007	Roche Organ Transplantation Research Foundation 124720319 Principal Investigator: C. Ferran Title: Transplant arteriosclerosis: role of A20 in homing of endothelial and smooth muscle cell progenitors
June 2006-May 2010	NIH/ NHLBI 1RO1 HL080130 Principal Investigator: C. Ferran Title: Vascular remodeling in transplant arteriosclerosis

July 1997- June 2009	NIH/NHLBI T32 HL00734-10 Co-director: C. Ferran Director: Dr. Frank W. LoGerfo Title: Longwood Research Training in Vascular Surgery The competitive renewal of received a score of 129 and **we expect it to be renewed until June 2014**
Feb 2007-Jan 2011	NIH/NHLBI RO1HL086741 Co-Investigator: C. Ferran Principal Investigator: Dr. Frank W. LoGerfo Title: Genetic engineering of vein bypass grafts in vascular and cardiovascular surgery
June 2007-May 2008	JDRF grant #5-2006-736 Co-Investigator: C. Ferran Principal Investigator: Dr. Elzbieta Kaczmareck Title: Protection of endothelial cell dysfunction by P2 receptor signaling
July 2007-June 2008	National Science Foundation #071141 Subcontractor: C. Ferran Principal Investigator: Matthew Phaneuf, Biosurfaces Title: STTR Phase I: Localized gene delivery from implantable arterial devices
Sept 2007-August 2010	JDRF #1-2007-567 Principal Investigator: C. Ferran Title: The therapeutic potential of A20 in diabetic retinopathy
August 2007-July 2012	NIH T32 AI070085 Faculty: C. Ferran Director: Dr. John Iacomini Title: Harvard Longwood Medical Area Training Grant in Transplantation

TEACHING EXPERIENCE

1. LOCAL CONTRIBUTIONS

University of Medicine Paris, Paris, France

1. University of Medicine Paris VI, Paris, France

1984-1988 Didactic sessions in Nephrology, Dialysis and Transplantation for medical students and nursing staff. (8-10 medical students per semester, 20-30 nurses per semester), Necker Hospital Paris, France. Estimate of contact time is 250 hours per year

1991-1993 Cochin Hospital, Paris, France

Lecturer at the Biotechnology Post-graduate Diploma on the topic of Diagnostic and Therapeutic Use of Monoclonal Antibodies
40 fellows, practitioners (CME)
Preparation 20 hours, contact time: 8 hours

2. University of Medicine Paris V, Paris, France

1990-1991 Necker Hospital, Paris, France
Lecturer in Seminars of the French Nephrology Boards on the topic of Immunodeficiency associated with End-stage Renal Failure
30 to 40 residents and fellows
Preparation required 50 hours, contact time with students: 8 hours

1990-1992 Centre de transfusion sanguine, Paris, France
Lecturer in the post-graduate Hematology Certificate on the topic of Transplantation Immunology
25 fellows and 10 MD practitioners (CME)
Preparation 10 hours, contact time: 6 hours

1992-1993 Necker Hospital, Paris, France
Lecturer at the Post-graduate Immuno-Rheumatology diploma on the topic of Cytokine Assays,
25 fellows and practitioners (CME)
Preparation : 15 hours, contact time : 3 hours

3. University of Medicine Paris IX, Paris, France

1992 Institut Gustave Roussy of Cancerologie, Villejuif, France
Lecturer at The annual Post-Graduate Course of Oncology on the topic of the Therapeutical Use of Monoclonal antibodies
40 Fellows.
Preparation 5 hours, contact time: 2 hours

Boston University Medical School, Boston, MA

1. Graduate medical courses

2000 Lecturer at the Graduate Immunology Training Seminars on the Protective Regulatory Response of EC and SMC to Injury
Preparation: 20 hours, contact time 6 hours including meeting with faculty and graduate students

Harvard Medical School

1. Undergraduate Courses

2004-2008 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Lecturer at the Vascular Biology Course for undergraduate summer students
Topic: The Vascular Response to Injury in Health and disease.
Preparation: 10 hours, contact time 2hours

2. Local invited teaching presentations

1998 Beth Israel Deaconess Medical Center, Harvard medical School
Lecturer at the Weekly Transplantation Seminars
Title: Xenotransplantation and Beyond
Transplant Surgeons, Nephrologists, Fellows, Residents and Interns
Preparation: 8 hours, 1 hour lecture

1999 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Weekly Transplantation Seminars
Title: Protective Role of the Anti-apoptotic Genes against Graft Rejection
Transplant Surgeons, Nephrologists, Fellows, Residents and Interns
Preparation: 8 hours, 1 hour lecture.

2001 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Research Seminar of the Department of Surgery
Title: Cytoprotective Genes and Regulation of Vascular Injury
Surgery Attendings and Principal Investigators, Fellows, Residents and Interns
Preparation: 8 hours, 1 hour lecture.

2002 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Research Seminar of the Department of Surgery
Title: Cytoprotective Genes and Regulation of Inflammatory Responses
Surgery Attendings and Principal Investigators, Fellows, Residents and Interns
Preparation: 8 hours, 1 hour lecture

2003 Beth Israel/Deaconess Medical Center, Harvard Medical School
Lecturer at the Seminars in Vascular Biology, Center for Vascular Biology, May 28th 2003
Title: A20: an Atherosclerosis Defying Gene
Attendings, Principal Investigators and Trainees of the Center for Vascular Biology
Preparation: 6 hours, 1 hour lecture

2004 Beth Israel/Deaconess Medical Center, Harvard Medical School
Lecturer at the Clowes Visiting Professor, July 2nd 2004
Topic: A20 and the Molecular Basis of Prometheus Myth
Surgery Attendings and Principal Investigators, Fellows, Residents and Interns
Preparation: 6 hours, 1 hour lecture

2005 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Grand Rounds of the Pathology Department, February 25th 2005
Topic: A20 and Atheroprotection
Principal Investigators, Post-doctoral Fellows, Graduate Students and Interns of the Department of Pathology
Preparation: 6 hours, 1 hour lecture

2005 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at Vascular Biology Seminars, April 27th 2005
Topic: A20 and Atheroprotection.
Principal Investigators, Post-doctoral Fellows, Graduate students of the Center for Vascular Biology Research
Preparation: 6 hours, 1 hour lecture

2006 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Surgical Research Grand rounds, June 27th 2006
Topic: Protective Functions of A20 in Hepatocytes
Attendings, Principal Investigators, Post-doctoral Fellows, Graduate Students of the Department of Surgery
Preparation: 6 hours, 1 hour lecture

2007 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Annual Retreat of the Center of Vascular Biology
Topic: Sweet A20 and the Vascular Complications of Diabetes
Attendings, Principal Investigators, Post-doctoral Fellows, Graduate Students affiliated with the Center for Vascular Biology Research
Preparation 6 hours, 30 minutes lecture

2007 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Pulmonary Grand rounds
Topic: A20: the thrive to maintain and restore homeostasis
Attendings, Principal Investigators, Post-doctoral Fellows, Graduate Students affiliated with the Pulmonary Division and the Center for Sleep Apnea
Preparation 8 hours, 1 hour lecture

2007 Beth Israel/Deaconess Medical Center, Harvard Medical School
Lecturer at the Clowes Visiting Professor, November 13th 2007
Topic: Vascular disease and the failure of homeostatic responses
Surgery Attendings and Principal Investigators, Fellows, Residents and Interns
Preparation: 6 hours, 1 hour lecture

2008 Beth Israel/Deaconess Medical Center, Harvard Medical School
Lecturer at the Surgical Research Seminars, March 24th 2008.
Topic: Update on A20 and atherosclerosis.
Surgery Attendings and Principal Investigators, Fellows, Residents and Interns
Preparation: 6 hours, 1 hour lecture

Continuing Medical Education courses

1999 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Weekly Gastro-Enterology Seminars
Title: Protective Role of the Anti-apoptotic Genes against Graft Rejection, and Inflammatory Conditions mainly Hepatitis
GI Attendings, Fellows, Residents and Interns

Preparation: 8 hours, 1 hour lecture

2001 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Weekly Endocrinology Seminars
Title: Role of the Protective Gene A20 in the Protection of Islet Transplantation and type I Diabetes.
Endocrinology Attendings and Principal Investigators, Fellows, Residents and Interns
Preparation: 8 hours, 1 hour lecture

2002 Beth Israel Deaconess Medical Center, Harvard Medical School
I was a lecturer at the weekly Seminars of the Transplantation Division
Title: A20 Protects from Transplant Associated Vasculopathy
Surgery Attendings and Principal Investigators, Fellows, Residents and Interns
Preparation: 8 hours, 1 hour lecture

2002 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Surgery grand rounds
Title: The graft Unveils it Secrets : Cytoprotective Genes and Graft Rejection
Surgery Attendings and Principal Investigators, Fellows, Residents and Interns
Preparation: 8 hours, 1 hour lecture

2003 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Transplantation Grand Round, January 7th 2003
Title: A20 and Liver Regeneration
Surgery Attendings and Principal Investigators, Fellows, Residents and Interns
Preparation: 6 hours, 1 hour lecture

2003 Seminars in Vascular Biology, Children's Hospital, Harvard Medical School, Boston, MA, March 16th 2003.
Topic: Help the EC Live and let the SMC Die
Attendings, Principal Investigators, Post-doctoral Fellows, Graduate Students of the Vascular Biology community of HMS
Preparation: 6 hours, 1 hour lecture

2005 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Nephrology Seminars, November 7th 2005
Topic: A20 and Atheroprotection.
Attendings, Principal Investigators, Post-doctoral Fellows, Graduate Students of the Nephrology Department
Preparation: 6 hours, 1 hour lecture

2005 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Transplant Center Seminars, December 20th 2005
Topic: The Multiple Targets of A20 in the Liver.
Attendings, Principal Investigators, Post-doctoral Fellows, Graduate Students of the Transplant Center

Preparation: 6 hours, 1 hour lecture

2005 Invited lecturer at the Vascular Biology Grand Rounds of the Brigham's and Women Hospital, Harvard Medical School, Boston, MA, March 29th 2005.
Topic: A20 and Atheroprotection
Attendings, Principal Investigators, Post-doctoral Fellows, Graduate Students of the Vascular Biology Center
Preparation: 8 hours, 1 hour lecture

2008 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at the Transplantation grand rounds, the Transplant Center, March 18th 2008.
Topic: Evading ischemia reperfusion to injury to improve outcomes of liver transplantation
Transplant Surgery Attendings and Principal Investigators, Post-doctoral Fellows, Residents and Interns
Preparation: 8 hours, 1 hour lecture

2009 Beth Israel Deaconess Medical Center, Harvard Medical School
Lecturer at a Workshop organized by the Center for Faculty Development Women's Subcommittee, February 23, 2009
Topic: The Roadmap to a successful scientific collaboration
Faculty from all Departments Beth Israel Deaconess Medical Center
Preparation: 10 hours, 2 hours discussion

Advisory and supervisory responsibilities in clinical or laboratory settings

1993-1995 Research Fellow, Beth Israel Deaconess Medical Center, responsible of supervising the research of 2 MD Surgery residents during their 2 years post-doctoral research training. Research projects involved the cytoprotective role of the anti-apoptotic gene A20 in endothelial cells. Estimate of contact time is 600 hours per year

1995-1997 Instructor of Surgery, Assistant Scientist, Beth Israel Deaconess Medical Center, responsible of supervising the research of 2 post-doctoral fellows (1 MD and 1 PhD) and 2 PhD candidates. Research projects involve genetic engineering of transplanted islets of Langerhans with anti-apoptotic "protective" genes for the treatment of type I diabetes, genetic engineering of smooth muscle cells with the anti-apoptotic "protective" genes for the inhibition of atherosclerosis and evaluation of the mechanism of action and structure-function relationships of A20 and the bcl anti-apoptotic genes in endothelial cells and gene therapy means to protect from acute hepatitis. Estimate of contact time is 40-50 hours per week

1997-1999 Assistant Professor of Surgery, Associate Scientist, Beth Israel Deaconess Medical Center. Responsible of directing the research of a group of scientists comprised of an instructor in Surgery (PhD), a visiting Assistant Professor in

Transplant Nephrology (MD), five post-doctoral fellows (1MD, 3 PhD and a surgical resident). Research projects involve the same topics discussed above in addition to the study of the protective effect of anti-apoptotic genes in protecting against acute toxic or viral hepatitis. Estimate of contact time is 50 hours per week

1999-2000 Associate Professor of Surgery, Staff Physician, Beth Israel Deaconess Medical Center, Responsible of directing the research of a group of scientists comprised of an instructor in Surgery (PhD), a visiting Assistant Professor in Transplant Nephrology (MD.), five post-doctoral fellows (1MD, 3 PhD and 2 surgical residents) and two summer students. Research projects involve the same topics discussed above. Estimate of contact time is 50 hours per week

2000-present Associate Professor of Surgery and Medicine, Staff Physician, Beth Israel Deaconess Medical Center. responsible of directing the research of a group of scientists comprised of one visiting Associate Professor (MD), one Assistant Professor (PhD), one Instructor (PhD), three post-doctoral fellows (1 PhD and 2 surgical residents), one graduate student (MS), 2 undergraduate students and 1-3 summer students. Research projects involve the same topics discussed above. Estimate of contact time is 50 hours per week.

Names of advisees or trainees

1993-1996 Maria T. Millan MD, Post-doctoral Fellow, Surgical Resident at the Beth Israel Deaconess Medical Center. Current position: Attending Liver Transplant Surgeon, Associate Professor of Surgery, Stanford University CA

1993-1997 Jeffrey T. Cooper MD, Post-doctoral Fellow, Surgical Resident at the Beth Israel Deaconess Medical Center. Current position: Attending Transplant Surgeon, Associate Professor of Surgery, Tufts University, Boston, MA

1994-1998 Deborah M. Stroka, PhD candidate, graduation 1998. Current position: Assistant Professor, University of Bern, Switzerland

1995-2000 Anne Z. Badrichani, PhD candidate, graduation 1998. Current position: Senior Scientist, Paris, France

1996-2003 Shane T. Grey, PhD Post-doctoral fellow. Current position: Associate Professor, The Garvan Institute for Medical Research, Sydney, Australia

1997-2002 Maria B. Arvelo, MD Research Associate. Current position: on maternity leave

1998- 2001 Jerome Mahiou, PhD, Post-doctoral Fellow. Current position: Senior Scientist at SyntaPharma, Lexington, MA

1998-2000 Eduardo Rocha, MD, Transplant Nephrologist from the University Federal of Rio de Janeiro, Brazil, PhD candidate from the University of Sao Paulo, Brazil,

completed his PhD in the laboratory as a visiting Assistant Professor. Current Position: Professor of Nephrology. University Federal of Rio de Janeiro, Rio de Janeiro, Brazil

Summer 1998 Christina Kaldany, MS, University of McGill Montreal, Canada. Completed her summer training in the laboratory. PhD in Neurosciences Tufts University, Boston, MA. Current Position: Associate Analyst in the Intellectual Property Office at Boston University, Boston, MA

1999-2008 Soizic Daniel, PhD, staff PhD. Current position: Principle Investigator, Institut National de Sciences et de Recherche Médicales (INSERM), Hôpital Necker, Paris, France

1999- 2002 Christopher R. Longo, MD, Post-doctoral Fellow, Surgical Resident at the Beth Israel Deaconess Medical Center. Recipient of a fellowship training grant from the Longwood Vascular Biology Training Program, a T32 NIH training program headed by Dr. F. LoGerfo. Current position: Attending in Vascular Surgery, Langley, North Carolina, USA.

Summer 2000 Monet France, medical student at UMDNJ. Recipient of the William J. Von Liebig Summer Research Scholar Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA. Current position: Resident in Orthopedic Surgery

2000-2002 Uta Kunter M. Nephrologist, Visiting Research Fellow, University of Aachen, Germany. Current position: Nephrology Attending at the University of Aachen, Germany

2000-2001 Rami Najjar, MS, Research Associate. Current position: Technical Director, New England Biolabs, Boston, MA

2001 Silke von Juergensson, MD, Surgical Research Fellow, University of Aachen, Germany. Current position: Research Fellow, University of Aachen, Germany

Summer 2001 Janis Traube, Medical Student, Tulane University, New Orleans. Recipient of the William J. Von Liebig Summer Research Scholar Program. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA. Current position: Resident in Pathology, Cornell University, New York

2001-2004 Virendra I. Patel, MD, Post-doctoral Fellow, Surgical Resident at the Beth Israel Deaconess Medical Center. Recipient of a fellowship training grant from the Longwood Vascular Biology Training Program, a T32 NIH training program headed by Dr. F. LoGerfo. Recipient of the NIH Loan repayment program (LRP) award. Current position: Attending in Vascular Surgery, Massachusetts General Hospital, Instructor of Surgery, Harvard Medical School, Boston, MA

Summer 2002 Kimberly Chong, Medical Student, University of Vermont. Recipient of the William J. Von Liebig Summer Research Scholar Program. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA

2002 Jessica Thaxton, BS, Research Assistant. Current position: PhD candidate, Brown University, Providence, RI

Summer 2003 Najeeb Tarazi, undergraduate student, Harvard University, Cambridge, MA. Current position: Employee at PIXAR, San Francisco, CA

Summer 2003 Jean Choi, undergraduate student, MIT, Cambridge, MA

Summer 2003 Caroline Groft. Medical Student, Cornell University, New York, NY. Recipient of the William J. Von Liebig Summer Research Scholar Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA

2002-2004 Tala Shukri, BS, Research Associate

2003-2005 Gautam V. Shrikhande, MD, Post-doctoral Fellow, Surgical Resident at the Beth Israel Deaconess Medical Center. Recipient of a fellowship training grant from the Longwood Vascular Biology Training Program, a T32 NIH training program headed by Dr. F. LoGerfo. Recipient of the NIH Loan repayment program (LRP) award. Current position: Fellow in Vascular Surgery, New York Presbyterian Hospital, Columbia and Cornell Universities, New York, NY

2003-2004 David Sun, senior PhD. Current position: Scientist. Washington DC.

2004-2007 Roy Arjoon, undergraduate student, Biomedical Engineering Program, Boston University, Boston, MA. Recipient of the Beckman Scholarship for undergraduate achievements at Boston University. This scholarship was partly based on the work performed by R. Arjoon in our laboratory. Early admission at BU Medical School. Co-supervisor of his senior year research project at Boston University Biomedical Engineering. Project title: Exploring a link Between A20 expression and Vascular Wall Biomechanics. Current position: Medical student, Boston University Medical School, Boston MA

2004-2006 Salvatore Scali, MD. Post-doctoral fellow, Surgical Resident at the Beth Israel Deaconess Medical Center. Recipient of a fellowship training grant from the Longwood Vascular Biology Training Program, a T32 NIH training program headed by Dr. F. LoGerfo. Current position: Fellow in Vascular Surgery, Dartmouth-Hitchcock Medical Center, Dartmouth University, Lebanon, NH

Summer 2004 Jeremiah Smith. Medical Student, University of Central Illinois. Recipient of the William J. Von Liebig Summer Research Scholar Program. Beth Israel Deaconess Medical Center

2004-2005 Himani Patel, undergraduate student, Boston University, Boston, MA

2005-2007 Haley Ramsey, MS thesis, University of Cologne, Germany. Current position: Research Associate in the laboratory at the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA. Current position: PhD candidate, Medical University of Vienna, PhD Program Inflammation and Immunity.

Summer 2005 Robert Bolash, medical student. University of Miami. Recipient of the William J. Von Liebig Summer Research Scholar Program, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA

2005-present Mark D. Fisher, MD, Post-doctoral Fellow, Surgical Resident at the Beth Israel Deaconess Medical Center. Recipient of a fellowship training grant from the Longwood Vascular Biology Training Program, a NIH T32 training program headed by Dr. F. LoGerfo. Recipient of the Loan Repayment Program (LRP) Award from the NIH. Current position: Clinical Fellow in Burn Surgery, Galveston, Texas

2006-2007 Nicholas Ward, undergraduate student, Harvard University, Boston, MA

2006-2007 Rakesh Patel, undergraduate student, Biomedical Engineering Program, Boston University, Boston, MA. Supervisor of his senior year research project, Boston University Biomedical Engineering. Project title: Delivery of genetic material to the cellular surface via a novel nanofibrous material

2006-2007 Michaela Matthey, MS thesis, University of Cologne, Germany. Current position: PhD. Candidate, University of Cologne, Germany

Summer 2006 Lynn Choi, medical student, New York University. Recipient of the William J. Von Liebig Summer Research Scholar Program. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA

2007-2008 Lynn Choi, Recipient of the Howard Hughes Fellowship for Medical Students. Current position: Medical student, University of Massachusetts, Worcester, MA

2006-2008 Elizabeth Maccariello MD, Visiting Associate Professor, University Federal of Rio de Janeiro, Brazil. Current position: Associate Professor at the University Federal of Rio de Janeiro, Brazil

2006-present Cleide Da Silva PhD, Instructor of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Recipient of a two-years post-doctoral fellowship grant award from the Juvenile Diabetes Research Foundation International; JDRF fellowship grant #3-2006-617

2006-present Elzbieta Kaczmarek PhD, Assistant Professor of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

2007-present Jeffrey Siracuse, MD. Post-doctoral Fellow, Surgical Resident at the Beth Israel Deaconess Medical Center. Recipient of a fellowship training grant from the

Longwood Vascular Biology Training Program, a T32 NIH training program headed by Dr. F. LoGerfo

2007-present Scott Damrauer, MD. Post-doctoral Fellow, Surgical Resident at the Massachusetts General Hospital, Boston, MA. Recipient of a fellowship training grant from the Longwood Vascular Biology Training Program, a T32 NIH training program headed by Dr. F. LoGerfo

Summer 2007 Karam Moon, medical student, Case Western Reserve University, Cleveland Ohio. Recipient of the William J. Von Liebig Summer Research Scholar Program. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA

2008-present Marco Skroch, MS thesis in preparation for PhD. University of Cologne, Germany

Summer 2008 Roy Arjoon, medical student, Boston University Medical School. Recipient of the William J. Von Liebig Summer Research Scholar Program. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA

Summer 2008 Anish Gevarghese, BS, Summer fellowship. Current medical student, Boston University Medical School, Boston, MA. t

Summer 2008 Carl Geahchan, BS, Summer fellowship. Current medical student, Balamand School of Medicine, Balamand, Lebanon.

Summer 2008 Sacha Bridi, Summer fellowship. Current undergraduate student at McGill University, Montreal, Canada.

2008-present Peter Studer, MD, Post-doctoral Research Fellow, Surgical Fellow in the Visceral and Transplant Surgery Department, University Hospital of Bern, Switzerland

2009-present Sanah Essayagh, PhD, Post-doctoral Research Fellow. Holds a PhD in Molecular Biology from the University of Toulouse, France

2. REGIONAL, NATIONAL OR INTERNATIONAL CONTRIBUTIONS

Regional contributions

2003 Annual Symposium in Vascular Surgery The Colonnade Hotel, Boston, MA, January 16th , 2003. Topic: Atherosclerosis and A20

2003 Invited Speaker at the Transplantation Grand Rounds, Lahey clinic Worcester MA, February 2003. Topic: A20 and Liver transplantation

2005 Invited Lecturer at the 5th Boston Basic Science Seminar in Vascular Surgery, the Colonnade Hotel, Boston, MA, USA, January 20th 2005. Topic: Novel Therapeutic Leads to Prevent and Cure Intimal Hyperplasia

2007 Invited Faculty at the 22nd Annual Senior Project Conference, Boston University, Department of Biomedical Engineering. May 4 2007, Boston, MA

National contributions

1994 Invited Lecturer at the IBC USA Conference. Washington D.C. Topic: Xenotransplantation: Potential Issues beyond Natural Antibodies and Complement in Strategies for Successful Xenotransplantation

1994 Invited Lecturer at the 1994 Keystone Symposium on Diabetes. Park City, Utah. Topic: Xenogeneic Islet Transplantation. Xenografting. Molecular Mechanisms common to Types I and II Diabetes

1995 Invited Lecturer at the Pediatric Transplantation Meeting University of Chicago, Northwestern, Illinois. Topic: Xenotransplantation

1998 Invited Lecturer at the Transplantation Grand Round of the University of Minneapolis, Minnesota . Topic: The State of the Art in Xenotransplantation

1998 Invited Lecturer at the 31st Annual meeting of the American Society of Nephrology, November 1998, Philadelphia, PA. Topic: Anti-apoptotic and "protective" genes in graft rejection and acceptance.

2000 Invited Lecturer at the Transplantation Grand Rounds, October 2000, University of Cincinnati, OH. Topic: Genetic Engineering in Organ Transplantation

2002 Invited lecturer at the 2002 FASEB summer Research Conference on Transplantation Immunology. The Vermont Acadamy in Saxtons River, Vermont, June 15th 2002. Topic: Endothelial Cell Cytoprotection in Transplantation

2002 Invited lecturer at the Transplantation Grand Rounds, University of Pensylvania Medical Center, school of Medicine, Philadelphia, Pennsylvania, February 4-5 2002. Topic: Protective strategies to Overcome allograft Rejection

2006 Invited Lecturer at the XVIth meeting of the American Society of Transplant Surgeons (ASTS); Scottsdale, Arizona, January 16-20, 2006. Topic: Mentoring, Networking and Collaborations in Research

2007 Invited Lecturer at the Trans-Institute Angiogenesis Research Program (TARP) annual workshop of the National Cancer Institute and National Heart Lung Blood Institute: Inflammation and the Perivascular environment. Bethesda MD,

November 18-20, 2007. Topic: Vascular Homeostasis: a casualty of unfettered inflammation

2008 Invited Lecturer at the Third Gordon Conference on "Endothelial Phenotypes in Health and Disease". The University of New England, ME. August 2-8, 2008. Topic: A20 and the thrive to restore vascular homeostasis

International contributions

1997 Invited Lecturer at the Annual Nephrology Meeting of Necker Hospital, Paris France. Topic: Xenotransplantation

1997 Invited Lecturer at the 4th Meeting of the Arab Society of Nephrology and Transplantation, Beirut, Lebanon. Topics: New Immunosuppressive Protocols in Organ Transplantation and Advances in Xenotransplantation

1998 Invited Lecturer at the Annual Transplantation seminars of Nantes, France. Topic: Genetic Engineering in Transplantation

1998 Invited Lecturer The Transplantation Club. Paris, France. Topic: The Mechanisms of Delayed Xenograft Rejection

1999 Invited Lecturer at the Egyptian Society of Nephrology, Cairo, Egypt. Topics: Xenotransplantation and the Use of New Immunosuppressive Regimen in Allotransplantation

2000 Invited Lecturer at a Transplantation Course organized by the Brazilian Society of Transplantation, March 21-24, Buzios, Brazil. Topics: Vascular Biology and Transplantation and Gene Therapy in Organ Transplantation

2000 Invited Lecturer at the 96th American Thoracic Society. Topic: The role of Bcl-2 Genes in Apoptosis, May 5-10 Toronto, Canada

2000 Invited Lecturer at the VIIth International Congress of the Middle Eastern Society of Organ Transplantation June 8-11, Beirut, Lebanon. Topics: Gene therapy in Organ Transplantation and Xenotransplantation

2000 Invited Lecturer at the European Symposium for Diabetes, August 11-14, Keble College. Oxford. United Kingdom. Topic: Protective Genes in Islet Transplantation and Autoimmunity

2001 Invited Lecturer at the Sixth International Conference on Tolerance Induction, Tucson, Arizona, January 21-24, 2001. Topic: Gene therapy in Tolerance Induction

2001 Invited Lecturer at Basic Science Symposium of the Transplantation Society. Thun, Switzerland, August 21-26, 2001. Topic: Protective Genes and Tolerance Induction

2001 Invited Speaker, at the VI Congress of the International Xenotransplantation Association. Chicago, Illinois, September 29-October 3, 2001. Plenary session, Topic: "Endothelial protective Strategies".

2001 Invited Speaker at the 2nd International Congress on Immunosuppresion. San Diego, California, December 5-8, 2001. Plenary session, topic: Strategies to Overcome chronic Rejection

2002 Invited Speaker at annual meeting of the Royal Society of Medicine. London, UK, March 20, 2002. Topic: Xenotransplantation

2002 Invited Speaker and session Chair at the annual meeting of the Transplantation Societies of Australia and New Zealand. Canberra, Australia, April 10-12th, 2002. Topic: Protective Strategies to Overcome Allograft Rejection

2003 Invited Lecturer at the VIIth International Xenotransplantation Congress. Glasgow, September 30th -October 4th 2003. Topic: Protective genes in Xenotransplantation

2004 Invited Lecturer at the Middle Eastern Society for OrganTransplantation, Ankara, December 2004. Topic: Xenotransplantation: Sate of the Art

2005 Invited Lecturer at the 5th Beaune Seminar in Transplant Research, Beaune, France, June 2nd and 3rd 2005. Topic: Expression of Protective Genes in Endothelial Cells

2005 Invited Lecturer at the IXth Brazilian Congress of Organ Transplantation, July 1-6 2005, Bahia, Salvador, Brazil. Topic: Protective genes in Cellular and Vascularized Organ Transplants

2006 Invited Speaker at the World Transplant Congress 2006, WTC 2006, July 22-27 2006, Boston, MA. Topic: Gene therapy in organ Transplantation, Which gene, Which cell, what time?

2008 Invited lecturer at the Faculdade de Medicina Christus, Fortaleza, Brasil. October 24-30 2008.

PROFESSIONAL AND EDUCATIONAL LEADERSHIP ROLES

1996 Session Chair at the XVIth International Congress of Organ Transplantation, Barcelona, Spain

1997 Session Chair at the IVth International Xenotransplantation Meeting, Nantes, France

1999 Session Chair at the Vth International Xenotransplantation Meeting. October 1999, Nagoya, Japan

2000 Moderator of a Workshop on Gene Therapy in Organ Transplantation, at the Transplant 2000 meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, May 13-17, Chicago, IL, USA

2000 Session Chair at the XVIIIth International Meeting of the Transplantation Society, August 27- September 1st, Rome, Italy

2001 Session chair at the Basic Science Symposium of the Transplantation Society. Thun, Switzerland, August 21-26, 2001. Session: Protective Genes in Transplantation

2006 Session Chair at the World Transplant Congress 2006, WTC 2006, July 22-27 2006, Boston, MA. Session: Genetic Engineering, Genomics and Proteomics

2008-Present Head of the Subcommittee for Junior Faculty at the Center for Vascular Biology Research, Beth Israel Deaconess Medical Center

REPORT OF CLINICAL ACTIVITIES

Clinical Practice mainly involves Transplant and general Nephrology and is performed on site at the Beth Israel Deaconess Medical Center.
The clinical contributions have been so far in the use of monoclonal antibodies in organ transplantation.

PUBLICATIONS

1. ORIGINAL PUBLICATIONS

1. Chatenoud L., **Ferran C**., Legendre C., Franchimont P., Reuter A., Kreis H., and Bach J.F. Clinical use of OKT3: The role of cytokine release and xenosensitization. J. of Autoimmunity. 1988, 1: 631-640.

2. Chatenoud L., **Ferran C**., Reuter A., Legendre C., Gevaert Y., Kreis H, Franchimont P. and Bach J.F. Activation Lymphocytaire T induite in vivo par la première injection de l'anticorps monoclonal OKT3. C. R. Acad.Sciences, 1988 307: 833-836.

3. Chatenoud L., **Ferran C**., Reuter A., Legendre C., Gevaert Y., Kreis H., Franchimont P. and Bach J. F. Systemic anti-T cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon gamma. New Engl. J. Med. 1989. 320 : 1420-1421

4. **Ferran C**., Sheehan K., Dy M., Schreiber R., Merite S., Landais P., Noël L.H., Grau G., Bluestone J., Bach J.F. and Chatenoud L. Cytokine related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 1990, 20: 509- 515.

5. Chatenoud L., **Ferran C**., Legendre C., Thouard I., Reuter A., Gevaert Y., Kreis H., Franchimont P., Bach J.F. In vivo cell activation following OKT3 administration : systemic cytokine release and modulation by corticosteroids. Transplantation , 1990, 49: 697-702.

6. **Ferran C**., Dy M., Merite S., Sheehan K., Schreiber R., Leboulenger F., Landais P., Bluestone J., Bach J.F. and Chatenoud L. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation, 1990, 50: 642-648 .

7. Chatenoud L., Legendre C., **Ferran C**., Bach J.F. and Kreis H. Corticosteroids inhibition of the OKT3 induced cytokine related syndrome- Dosage and kinetics prerequisites. Transplantation 1991, 51: 334- 338.

8. **Ferran C**., Dy M., Sheehan K. , Merite S., Schreiber R. , Landais P. , Grau G., Bluestone J., Bach J.F. and Chatenoud L. Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release. Clin. and Exp. Immunol. 1991, 86: 537-543.

9. **Ferran C**., Dy M., Sheehan K., Schreiber R., Landais P., Grau G., Bluestone J., Bach J.F. and Chatenoud L. Cascade modulation by anti-TNF monoclonal antibody of IFNγ, IL-3 and IL-6 release after triggering of the CD3/TCR activation pathway. Eur. J. of Immunol. 1991, 21: 2349-2353.

10. Charpentier B., Hiesse C., Lantz O., **Ferran C**., Stephens S., O'Shaugnessy D., Bodmer M., Fries D., Bach J.F. and Chatenoud L. Anti-human Tumor Necrosis Factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992, 54: 997-1002.

11. **Ferran C.** T lymphocyte activation induced in vivo in different strains of mice after injection of anti-CD3 antibodies: prevention by an anti- TNF antibody. Nephrologie, 1993, 14: 23-24.

12. **Ferran C**., Peuchmaur M., Desruennes M., Ghoussoub J.J, Cabrol A., Brousse N., Cabrol C., Bach J.F. and Chatenoud L. Implications of de novo ELAM-1 and VCAM-1 expression in human cardiac allograft rejection. Transplantation, 1993, 55: 605-609.

13. **Ferran C.,** Dautry F., Merite S., Sheehan K., Schreiber R.D., Grau G., Bach J.F. and Chatenoud L. Anti-TNF modulates anti-CD3 triggered T cell cytokine gene expression in vivo. J. Clin. Invest. 1994, 93: 2189 – 2196.

14. **Ferran C**, Millan MT, Csizmadia V, Cooper JTC, Brostjan C, Bach FH and Winkler H. Inhibition of NF-κB by pyrrolidine dithiocarbamate blocks endothelial cell activation. Bioch. Bioph. Res. Comm. 1995, 214 (1): 212-223.

15. Bach FH, Robson SC, Hancock WW, Wrighton C, **Ferran C** and Winkler H. Genetic Engineering of endothelial cells to ameliorate xenograft rejection. Clinical Transplantation, 1996, 10: 124-127.

16. Goumy L, **Ferran C**, Merite S, Bach JF and Chatenoud L. In vivo anti-CD3-driven cell activation: Cellular source of induced tumor necrosis factor, Interleukin-1β and Interleukin 6. Transplantation, 1996, 61: 83-87.

17. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH and **Ferran C**. A20 blocks endothelial cell activation through a NF-κB-dependent mechanism. J. Biol. Chem., 1996, 271: 18068-18073.

18. Bach FH, **Ferran C**, Hechenleitner P, Mark W, Miyatake T, Koyamada N, Candinas D and Hancock WW. Accomodation of vascularized xenografts: Expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nature Medicine, 1997, 3: 1-9.

19. Millan MT, Geczy C, Stuhlmeier KM, Goodman DJ, **Ferran C** and Bach F.H. Human monocytes activate porcine endothelial cells resulting in increased E-selectin, Interleukin-8, monocyte chemotactic protein-1, and plasminogen activator inhibitor-type-1 expression. Transplantation,1997, 63: 421-429.

20. **Ferran C**, Stroka DM, Badrichani AZ, Cooper JT, Wrighton CJ, Soares M. Grey ST and Bach FH.A20 Inhibits NF-κB Activation in Endothelial Cells without Sensitizing to TNF-mediated Apoptosis. Blood, 1998, 91: 2249-2258.

21. Soares M.P, Amuniapp A., Kaczmarek E, Koziak K, Wrighton CJ, Steinhäuslin F, **Ferran C**, Winkler H, Bach FH, Anrather J. Overexpression of a transdominant negative mutant of p65/RelA inhibits NF-κB without sensitizing to apoptosis. J. Immunol. 1998, 161:4572-4582.

22. Von Albertini M, **Ferran C**, Brostjan C, Bach FH and Goodman DJ. Membrane-associated lymphotoxin on natural killer cells activates endothelial cells via an NF-κB-dependent pathway. Transplantation, 1998, 66: 1211-1219.

23. Bach F.H., **Ferran C**., Soares M., Wrighton C.J., Anrather J., Winkler H., Robson S.C. and Hancock W.W. Modification of vascular responses in xenotransplantation: inflammation and apoptosis. 1998: Nature Medicine, 3: 944-948.

24. Badrichani AZ, Stroka DM, Bilbao G, Curiel DT, Bach FH and **Ferran C**· Bcl-2 and Bcl-X_L Serve an Anti-inflammatory Function in Endothelial Cells Through Inhibition of NF-κB. J. Clin. Invest. 1999, 103: 543-553.

25. Stroka DM, Badrichani AZ, Bach FH and **Ferran C**: A1: A NF-κB-inducible, Anti-Apoptotic Bcl Gene that inhibits Endothelial Cell Activation. Blood 1999, 93: 3803-3810.

26. Grey ST, Arvelo MB, Hasenkamp WM, Bach FH and **Ferran C**. A20 inhibits cytokine-induced apoptosis and NF-κB dependent gene activation in islets. J. Exp. Med. 1999. 190: 1135-1145.

27. Millan MT, Natkunam Y, Clarke-Katzenberg R., Desai D, Prapong W, So SK Esquivel CO, **Ferran C** and Martinez O. EBV infection is associated with endothelial bcl-2 expression in transplant liver allografts. Transplantation, 2002, 73: 465-469.

28. Avihingsanon, Y, Ma N, Csizmadia E, Wang C, Pavlakis M, Strom TB, Soares M and **Ferran C.** Expression of protective genes in human renal allografts: a regulatory response to injury associated with graft rejection. 2002, Transplantation, 73: 1079-1085.

29. Laybutt DR, Kaneto H, Hasenkamp W, Grey S, Jonas JC, Groff A, **Ferran C**, Bonner-Weir S, Sharma A, Weir GC. Increased expression of antioxidant and anti-apoptotic genes in islets that may contribute to beta-cell survival during chronic hyperglycemia. Diabetes, 2002, 51: 413-423.

30. Arvelo MB, Cooper JT, Longo C, Daniel S, Grey S, Mahiou J, Csizmadia E, Abujawdeh G, **Ferran C.** A20 protects mice from D-galactosamine/Lipolysaccharide acute toxic lethal hepatitis. Hepatology, 2002, 35: 535-543.

31. Künter U, Floege J, von Jurgenson AS, Stojanovic T, Merkel S, Grone HJ, **Ferran C.** Expression of A20 in the vessel wall of rat kidney allografts correlates with protection from transplant arteriosclerosis. Transplantation. 2003, 75: 3-9.

32. Grey ST, Longo C, Shukri T, Patel V, Cszismadia E, Daniel S, Arvelo M, Tchipashvili V, **Ferran C**. genetic engineering of a suboptimal islet graft with A20 preserves β-cell mass and function. J. Immunol. 2003, 170: 6250-6256.

33. Longo CR, Arvelo MB, Patel VI, Daniel S, Mahiou J, Grey ST, **Ferran C**. A20 protects from CD40/CD40L mediated endothelial cell activation and apoptosis. Circulation, 2003, 108: 1113-1118.

34. Makhlouf L, Grey ST, Dong V, Csizmadia E, Arvelo MB, Auchincloss, H Jr., **Ferran C***, Sayegh MH* (*co-last authors). Depleting anti-CD4 monoclonal antibody cures new onset, prevents recurrent autoimmune diabetes and delays allograft rejection in nonobese diabetic mice. Transplantation, 2004, 77: 990-997.

35. Song R, Zhou Z, Kim PKM, Shapiro RA, Liu F, **Ferran C**, Choi AMK, Otterbein LE. Carbon monoxide promotes Fas/CD95-induced apoptosis in Jurkat cells. J. Immunol. 2004. 44:44327-44334.

36. Daniel S, Arvelo MB, Patel VI, Longo CR, Shrikhande G, Shukri T, Mahiou J, Sun DW, Mottley C, Grey ST, **Ferran C**. A20 protects from TNF, Fas and NK mediated cell death by inhibiting caspase 8 activation. Blood, 2004: 104:2376-2384.

37. Storz P, Doppler H, **Ferran C**, Grey ST, Toker A. Functional dichotomy of A20 in apoptotic and necrotic cell death. Biochem. J, 2005, 387:47-55.

38. Avihingsanon Y, Ma N, Pavlakis M, Chon WJ, Giraldo M, Monaco AP, **Ferran C**, Stillman I, Schlachter AD, Mottley C, Zheng XX, Strom TB. On the intra-operative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J. Am. Soc. Nephrol. 2005, 16: 1542-1548.

39. Longo CR, Patel VI, Shrikhande GV, Scali ST, Csizmadia E, Daniel S, Sun DW, Grey ST, Arvelo MB, **Ferran C.** A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a $p21^{waf1}$ dependent mechanism. Hepatology, 2005, 42:156-164.

40. Künter U, Daniel S, Arvelo MB, Choi J, Shukri T, Patel VI, Longo CR, Scali ST, Shrikhande GV, Rocha E, Csizmadia E, Mottley C, Grey ST, Floege J, **Ferran C.** Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells. Kidney International, 2005, 68: 1520-1532.

41. Abid Md.R., Yano K, Guo, S, Patel VI, Shrikhande G, Spokes KC, **Ferran C**, Aird WC. Forkhead transcription factors inhibits vascular smooth muscle cell proliferation and intimal hyperplasia. J. Biol. Chem. 2005, 280: 29864-29873.

42. Shrikhande GV, Khaodiar L, Scali ST, Lima C, Hubbard M, Dudley K, Ganda O, **Ferran C**, Veves A. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces PARP activation. J. Vasc. Surgery, 2006, 43: 760-771.

43. Patel VI, Daniel S, Longo CR, Shrikhande G, Scali ST, Czismadia E, Groft C, Shukri T, Mottley-Dore C, Ramsey HE, Fisher MD, Grey ST, Arvelo MB, **Ferran C.** A20 a modulator of smooth muscle cell proliferation and apoptosis, prevents and cures neointimal hyperplasia. The FASEB J., 2006, 20: 1418-1430.

44. Daniel S, Patel VI, Shrikhande GV, Scali ST, Ramsey HE, Csizmadia E, Benhaga N, Fisher MD, Arvelo MB, **Ferran C**. The universal NF-κB inhibitor A20 protects from transplant vasculopathy by differentially affecting apoptosis in EC and SMC. Transpl. Proc. 2006, 38: 3225-3227.

45. Monahan TS, Andersen ND, Panossian H, Kalish JA, Daniel S, Shrikhande GV, **Ferran C**, LoGerfo FW. A novel function for Cadherin 11/Ob-Cadherin in vascular Smooth Muscle Cells: Modulation of Cell Migration and Proliferation. J. Vasc Surgery, 2007, 45: 581-589.

46. Andersen ND, Monahan TS, Malek, JY, Jaine, M, Daniel S , Caron LD, Pradhan L, **Ferran C**, and LoGerfo FW. Comparison of Gene Silencing in Human Vascular Cells Using Small Interfering RNAs. J Am Coll Surg, 2007, 204:399-408.

47. Monahan TS, Andersen ND, Martin MC, Malek JY, Shrikhande GV, Pradhan L, **Ferran C**, LoGerfo FW. MARCKS silencing differentially affects human vascular smooth muscle

and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein. FASEB Journal, 2009, 23; 557-564.

48. da Silva CG, Specht A, Wegiel B, Ferran C, Kaczmarek E. Mechanism of purinergic activation of endothelial nitric oxide synthase in endothelial cells. Circulation, 2009, 119; 871-879.

49. Tran TM, Temkin V, Shi B, Pagliari LJ, Daniel S, Ferran C, Pope RM. TNFα-induced macrophage death via caspase-dependent and independent pathways. Apoptosis, 2009, 14;320-332.

50. Ramsey HE, Da Silva C., Longo CR, Csizmadia E, Patel VI, Scali ST, Shrikhande GV, Choi L, Kaczmarek E, Maccariello ER, Damrauer SM, Siracuse JJ, Daniel S, **Ferran C.** A20 protects mice from lethal liver ischemia reperfusion injury by increasing PPARα expression. Liver Transplantation, 2009, accepted with revision.

2. CLINICAL COMMUNICATIONS

1. Grünfeld J. P., Landais P. and **Ferran C**. Traitement de l'hypertension artérielle par Enalapril chez les insuffisants rénaux. In La Presse Médicale, Dec., 14, n°44: 2213-2214, 1985

2. Chatenoud L., **Ferran C.** and Bach J.F. In vivo anti-CD3 treatment of autoimmune patients. Lancet 1989, II: 164.

3. PROCEEDINGS OF MEETINGS

1. Chatenoud L., **Ferran C**., Legendre C., Kreis H. and Bach J.F. In vivo immunosuppressive effect of the anti-human T cell receptor BMA 031 monoclonal antibody. European Society of Organ Transplantation, Barcelona, Spain , 1989. In Transplant Proc. 22, 1787-1788, 1990.

2. **Ferran C**, Bluestone J, Bach JF, Chatenoud L. In vivo T lymphocyte activation induced in mice following the injection of anti-CD3 monoclonal antibody. Transplant Proc. 22:1922-3. 1990.

3. Bach FH, Robson SC, **Ferran C**, Millan M, Anrather J, Kopp C, Lesnikoski B, Goodman DJ, Hancock WW, Wrighton C and Winkler H. Xenotransplantation: Endothelial cell activation and beyond in Transplant Proc. 27 (issue 1): 77-79, 1995.

4. Bach FH, Winkler H, Wrighton CJ , Robson SC, Stuhlmeier K and **Ferran C** Xenotransplantation: a Possible Solution to the Shortage of Donor Organs. In Transplant Proc, 28(1):416-417, 1996.

5. Bach FH, Soares M, Lin Y**, Ferran C**. Barriers to Xenotransplantation. The XVIIth International Congress of the Transplantation Society. Montreal, Canada, July 12-17, 1998. In Transplant Proc., 31: 1819-1820, 1999.

6. Badrichani AZ, Stroka DM, Bilbao G, Curiel DT, Bach FH and **Ferran C.** Expression of the anti-apoptotic Bcl members in endothelial cells serve a broad anti-inflammatory function that can favorably impact upon xenograft survival. 5th Congress of the International Xenotransplantation Association. Nagoya Japan, 1999.

7. Badrichani AZ, **Ferran C.** A20 and Bcl proteins exert a broad and complementary cytoprotective effect in endothelial cells via blockade NF-κB and NFAT. The XVIII International Congress of the Transplantation Society. Roma, Italy, 2000. In Transplant Proc. 22: 450. 2001.

8. Rocha E, Mahiou J, Badrichani AZ, Stroka DM, **Ferran C**. The BH4 domain of A1, an anti-apoptotic bcl family gene, is necessary and sufficient for its anti-inflammatory function in endothelial cells. The XVIII International Congress of the `Transplantation Society. Roma, Italy, 2000. In Transplant Proc. 33: 314, 2001.

4. REVIEWS/ CHAPTERS/ EDITORIALS

1. Grünfeld J.P., Noêl L.H.,Bobrie G., **Ferran C**., et al . Advances in the understanding of inherited renal diseases. (Editor: Davison A.), Proceedings of the Xth International Congress of Nephrology- in Nephrology, 1988, I, 637-660.

2. Bachener L., Albouze G., **Ferran C**.,Grünfeld J.P. and Kaplan J. Family studies of adult dominant polycystic Kidney disease (PKD 1 Locus) using the highly polymorphic probe 3'HVR-and the HBA locus for the neonatal recessive disease. IXth Int.Workshop of human gene mapping (HGM9).Cytogenet. Cell.Genet, 1987

3. Chatenoud L., **Ferran C**., Reuter A., Legendre C., Gevaert Y., Kreis H., Franchimont P., Bach J. F. The clinical syndrome following OKT3 Monoclonal antibody injection correlates with high levels of serum cytokines.. (D. Fradelizzi, J. Bertoglio Eds); In "Lymphokine Receptor Interactions" , John Libbey Paris , 1989, 179: 187-194 .

4. Chatenoud L., **Ferran C.** and Bach J. F. In vivo use of OKT3: Main issues for the monitoring of treated patients. Transpl. Proc. 22: 2605-2608, 1990.

5. Chatenoud L., **Ferran C**. et Bach J.F. Clinical applications of anti-T cell monoclonal antibodies.(M.H. Maxwell Eds). Advances in Nephrology, 1991, 20: 281-304.

6. Chatenoud L., **Ferran C**. and Bach J.F. The anti-CD3 induced syndrome: a consequence of massive in vivo cell activation. (B. Fleischer, H.O. Sjögreu Eds). Current Topics in Microbiology and Immunology. Superantigens 1992, 174, 146.

7. **Ferran C**., Bach JF and Chatenoud L. Les anticorps monoclonaux: Utilisations Diagnostiques et Thérapeutiques, Perspectives d'avenir. Revue Française de transfusion et d'hémobiologie, 1993, 36: 149-177.

8. **Ferran C**. Bach JF and Chatenoud L. In vivo T cell activation properties of anti-T cell Monoclonal Antibodies. Exp. Nephrol 1994.

9. Bach F.H., Robson S.C., **Ferran C**., Winkler H., Millan M.T., Stuhlmeier K.M., Vanhove B., Blakely M.L., van der Werf W.J., Hofer E., de Martin R. and Hancock W.W. Endothelial cell activation and thromboregulation during xenograft rejection. Immunological reviews. 1994, 141: 5- 30.

10. Millan, M.T., **Ferran C**., Winkler H., Blakely M.L., Van der Werf W., Hancock W., and Bach F.H. Xenotransplantation: Problems and approaches. Transpl. Proc. 1994, 26: 3593-3596.

11. Bach F.H., Robson S.C., **Ferran C**., Millan M., Anrather J., Kopp C., Lesnikoski B., Goodman D.J., Hancock W., Wrighton C., Winkler H. Xenotransplantation: endothelial cell activation and beyond. 1995, 27: 77-79.

12. Bach FH, Robson SC, Winkler H, **Ferran C**, Stuhlmeier KM, Wrighton CJ and Hancock WW. Barriers to xenotransplantation . Nature Medicine, 1995, 1; 869-873.

13. Bach F.H., Winkler H., Wrighton C., Robson S.C., Stuhlmeier K., **Ferran C**. Xenotransplantation: a possible solution to the shortage of donor organs. Transpl. Proc. 1996, 28: 416-417.

14. Winkler H., **Ferran C**. and Bach FH. Accomodation of xenografts: a Concept revisited. Xenotranspl. 1996, 2: 53-56.

15. Winkler H, **Ferran C** and Bach FH: NF-κB: a major control switch of endothelial cell activation. Xeno 1996, 4: 1-4.

16. Bach, F.H., Winkler H., **Ferran C**., Hancock W.W. and Robson S. Delayed xenograft rejection. Immunology Today. 1996,17: 379-384.

17. Bach FH, Hancock WW and **Ferran C**. Expression of protective genes expressed in endothelial cells: A regulatory response to injury. Immunology Today, 1997, 18: 483-486.

18. **Ferran C**, Badrichani AZ, Cooper JT, Stroka DM and Bach FH. Xenotransplantation: Progress towards clinical development.(M.H. Maxwell Eds). in Advances in Nephrology, 1997, 27: 391-420.

19. Soares. M.P., Lin, Y., Sato K., Takigami K., Anrather J., **Ferran C**., Robson S.C., Bach FH. Pathogenesis and potential therapies for delayed xenograft rejection. Opin. Organ Transplant 1999, 4:80-89.

20. **Ferran C**. and Bach FH. Xenotransplantation: Hopes and Goals in Transplantation Surgery, Editors Nadey Hakim and Gabriel Danovitch (Springer, Verlag, Eds) 2001, Chapter 15, p.343-353.

21. **Ferran C**. The graft unveils its secrets: Provocative therapeutic leads to protect vascularized organs. Transplant Immunol. 2002, 9: 135-136.

22. **Ferran C**. Protective genes in the vessel wall: Modulators of graft survival and function. Supplement Transplantation, 2006. 82S1: S36-40.

5. BOOKS

Ferran C: Editor. The Multiple Therapeutic Facets of A20
Publisher: Landes Bioscience, Springer. Text book in preparation, publication planned for March 2009

6. PATENTS

1. Christiane Ferran and Fritz H. Bach, inventors; Novartis Pharma assignee. Anti-apoptotic therapy for transplantation and inflammatory conditions and means therfor. Docket file 61807234, 1996.

2. Christiane Ferran, inventor. Beth Israel Deaconess Medical Center assignee. Use of pro-apoptotic factors in treatment of atherosclerosis. U.S. Serial No: 10/461,200. Publication number: US-2003-0207838-A1. Date of patent: September 18, 2007.

3. Christiane Ferran co-inventor: Measurement of protective genes in allograft rejection, Patent number: US 6,900,015 B2. Date of patent: May 31, 2005.

7. ABSTRACTS

1. Shrikhande GV, Scali ST, Daniel S, Patel VI, Arjoon R, Smith J, Csizmadia E, Dore C, Monahan T, Fisher MD, Veves A, Usheva A and Ferran C. Altered A20 expression in diabetes mellitus contributes to increased risk of atherosclerosis. Presented at the Annual Surgical Research Competition at the Beth Israel Deaconess Medical Center, June 2005.

2. Scali ST, Shrikhande GV, Bolash R, Fisher MD, Daniel S, **Ferran C**. A novel anti-angiogenic function of A20: Implications in diabetic retinopathy. Presented at the Annual Surgical Research Competition at the Beth Israel Deaconess Medical Center, June 2005.

3. Patel VI, Daniel S, Longo CR, Shrikhande G, Scali ST, Czismadia E, Groft C, Shukri T, Grey ST, Arvelo MB, **Ferran C**. A20 promotes regression of neointimal hyperplasia via a novel NO-dependent pro-apoptotic function in neointimal smooth muscle cells. Presented and awarded at the Annual Surgical Research Competition at the Beth Israel Deaconess Medical Center, June 2005.

4. Andersen ND, Monahan TS, Driscoll IR, Jain M, Caron LD, **Ferran C**, and LoGerfo FW. Gene Silencing in Human Vein Grafts: A Novel Tool for the Prevention of Intimal Hyperplasia. Accepted for oral presentation by the Society for University Surgeons for presentation at the Academic Surgical Congress, February 2006, San Diego, CA.

5. Andersen ND, Monahan TS, Jain M, Daniel S, **Ferran C**, and LoGerfo FW. An Ex Vivo Human Vein Knockdown Model Using Silencing RNA. Poster presentation at the National Heart Lung and Blood Institute's PGA Symposium, July 2005, Bethesda, MD.

6. Monahan TS, Andersen ND, Contreras MA, Phaneuf MD, **Ferran C**, and LoGerfo FW. Effects on Cellular Migration and Proliferation after siRNA-mediated Knockdown of PKC Substrates in Human Vascular Smooth Muscle and Endothelial Cells. Poster presentation at the North American Vascular Biology Organization, June 2005, Chicago IL.

7. Monahan TS, Andersen ND, Popescu-Vladimir A, Kalish JA, Contreras MA, Phaneuf MD, Daniel S, Shrikhande GV, **Ferran C**, and LoGerfo FW. RNA Interference Targeting MARCKS Arrests Human Vascular Smooth Muscle Cell Proliferation In Vitro and Ex Vivo. Oral presentation at the Society of University Surgeons, February 2005, Nashville, TN.

8. Andersen ND, Monahan TS, Jaine, M, Daniel S, **Ferran C**, and LoGerfo FW. Optimization of Rapid Silencing RNA Transfection of Human Vein Bypass Grafts. American College of Surgeons; 2006.

9. Longo CR, Ramsey HE, Patel VI, Scali ST, Shrikhande GV, Fisher MD, Csizmadia E, Daniel S, **Ferran C**. A20 protects the liver from lethal ischemia reperfusion injury by promoting hepatocyte proliferation, survival and function. Oral presentation at World Transplant Congress, July 22nd -27th 2006, Boston, MA. In Am J. Transplant, 2006, 6 (suppl 2) p.248.

10. Scali ST, Shrikhande GV, Fisher MD, Bolash R, Ramsey HE, Ward N, Daniel S, **Ferran C.** A Novel anti-angiogenic function for A20: Implications in transplant arteriosclerosis. Oral presentation at World Transplant Congress, July 22nd -27th 2006, Boston, MA. In Am. J. Transplant, 2006, 6 (suppl. 2) p.76.

11. Goncalves Da Silva C, Specht A, **Ferran C**, Kakzmarek E. Mechanism of extracellular nucleotide-induced eNOS activation in endothelial cells. Poster presentation at the Center for Vascular Biology Retreat, Beth Israel Deaconess Medical Center, February 9th 2007.

12. Shrikhande GV, Scali ST, Ramsey HE, Fisher MD, Csizmadia E, Daniel S, Patel VI, Arjoon R, Smith J, Da Silva C, Monahan T, Veves A, Kaczmarek E and **Ferran C.** Altered A20 expression in diabetes mellitus contributes to increased risk of atherosclerosis. Poster presentation at the Center for Vascular Biology Retreat, Beth Israel Deaconess Medical Center, February 9th 2007.

13. Scali ST, Fisher MD, Clermont A, Da Silva C, Csizmadia E, Shrikhande GV, Choi L, Bolash R, Ramsey HE, Daniel S, Kaczmarek E, Young M, Bursell S and **Ferran C.** A novel anti-amgiogenic function of A20: implications in diabetic retinopathy. Poster presentation at the Center for Vascular Biology Retreat, Beth Israel Deaconess Medical Center, February 9th 2007.

14. Da Silva CG, da-Shen X, Ke B, Csizmadia E, Kupiec-Weglinski J and **Ferran C**. A20 significantly improves survival and function of marginal liver grafts. Accepted for oral presentation at the American Transplant Congress, June 2008, Toronto, Canada.

15. Da Silva CG, Ramsey HE, Longo C, Csizmadia E and **Ferran C**. A20 Promotes Hepatocyte Proliferation by Enhancing IL-6 Signaling: A Mean to Improve Success of Small-for-Size Liver Grafts. Accepted for oral presentation at the American Transplant Congress, June 2008, Toronto, Canada.

16. Maccariello E, Da Silva CG, Daniel S, Damrauer SM, Choi LY, Siracuse JJ, Kaczmarek E and **Ferran C**. Hepatocyte Growth Factor upregulates A20 in renal proximal tubular epithelial cells: a potential protective preconditioning regimen in kidney transplantation. Accepted for oral presentation at the American Transplant Congress, June 2008, Toronto, Canada.

17. Siracuse JJ, Fisher MD, Csizmadia E, Damrauer SM, Choi LY, Da Silva CG, Moon K, Maccariello ER, Daniel S and **Ferran C**. A20 prevents transplant arteriosclerosis in a model of aortic allograft. Accepted for oral presentation at the American Transplant Congress, June 2008, Toronto, Canada.

18. Daniel S, Choi LY, Siracuse JJ, Fisher MD, Csizmadia E and **Ferran C**. A20 increases eNOS expression and activation to restore vascular homeostasis in the face of inflammation and protect from transplant arteriosclerosis. Accepted for poster presentation at the American Transplant Congress, June 2008, Toronto, Canada.

19. Damrauer SD, Fisher MD, Scali ST, Wada H, Da Silva CG, Csizmadia E, Maccariello ER, Moon K, Siracuse JJ, Bolash R, Aird W, Daniel S and **Ferran C**. Combined anti-inflammatory and anti-angiogenic functions of A20 in the vessel wall: Implications for transplant arteriosclerosis. Accepted for poster presentation at the American Transplant Congress, June 2008, Toronto, Canada.

20. Damrauer SD, Fisher MD, Scali ST, Wada H, Da Silva CG, Csizmadia E, Maccariello ER, Moon K, Siracuse JJ, Bolash R, Aird W, Daniel S and **Ferran C**. The atheroprotective molecule A20 inhibits post-angioplasty restenosis by both anti-inflammatory and anti-angiogenic pathways. Accepted for poster presentation at the Society for Vascular Surgery Annual Meeting, June 2008, San Diego, CA.

21. Siracuse JJ, Fisher MD, Csizmadia E, Damrauer SM, Choi LY, Da Silva CG, Moon K, Maccariello ER, Daniel S and **Ferran C**. A20 protects against accelerated atherosclerosis in aortic allografts. Accepted for oral presentation at the Society for Vascular Surgery Annual Meeting, June 2008, San Diego, CA.

22. Choi LY, Scali ST, Da Silva CG, Clermont A, Csizmadia E, Damrauer SM, Siracuse JJ, Young M, Benjamin L, Daniel S and **Ferran C**. A novel anti-angiogenic function of A20: Implications in diabetic retinopathy. Accepted for poster presentation at the 15th International Vascular Biology Meeting, June 2008, Sydney, Australia. Lynn Choi received a student travel award.

23. Siracuse JJ and **Ferran C**. A20 Protects Against Transplant Associated Vasculopathy. Winner of the Annual Beth Israel Deaconess Medical Center Department of Surgery Resident Research Competition, June 2008.

24. Maccariello E, Da Silva CG, Daniel S, Kaczmarek E and **Ferran C**. Hepatocyte Growth Factor activates non-canonical NF-κB pathway in human renal proximal tubular epithelial cells to induce the protective gene A20. Accepted for poster presentation at the American Society of Nephrology, November 4-9 2008, Philadelphia, PA.

25. Da Silva CG, Skroch M, Studer P, Damrauer SM, Siracuse JJ, Maccariello E, Kaczmarek E and **Ferran C**. The pro-proliferative effects of A20 map to the 7-Zinc finger domain: A means to define small peptides with therapeutic potential. Accepted for poster presentation at the American Transplant Congress, May 2009, Boston, USA.

26. Daniel S, Kaczmarek E, Choi L, Fisher MD, Siracuse SS, Csizmadai E, Damrauer SM, Studer P, da Silva CG, **Ferran C**. A20 increases the expression of endothelial and inducible nitric oxide synthases in endothelial and smooth muscle cells to protect from transplant arteriosclerosis. Accepted for poster presentation at the American Transplant Congress, May 2009, Boston, USA

27. Siracuse JJ, da Silva CG, Damrauer SM, Fisher MD, Studer P, Skroch M, Choi LY, Csizmadia E, Kaczmarek E, Daniel S, **Ferran C.** Opposinf effects of A20 upon CD40 expression in EC and SMC: Implication in A20's protective effect against transplant associated vasculopathy. Accepted for poster presentation at the American Transplant Congress, May 2009, Boston, USA

28. Siracuse JJ, da Silva CG, Damrauer SM, Fisher MD, Studer P, Skroch M, Choi LY, Csizmadia E, Kaczmarek E, Daniel S, **Ferran C.** A20's Opposite Effect on CD40 Expression in Endothelial Cells and Smooth Muscle Cells Underscores its Atheroprotective Potential. Accepted for oral presentation at the ***2009 SVS Research Initiatives in Vascular Disease Conference***, April 28, 2009,Washington, D.C